Sugi Predict
/ Targets
/ CCNI
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to CCNI by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt |
PHASE4 | COMPLETED |
| A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) |
PHASE3 | COMPLETED |
| Effect of Silymarin in Metastatic Colorectal Cancer Patients |
PHASE3 | UNKNOWN |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| Histology-Independent Study of Palbociclib in Patients With Advanced Cancer |
PHASE2 | WITHDRAWN |
| Study of AVZO-021 in Patients With Advanced Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) |
PHASE1/PHASE2 | RECRUITING |
| Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression |
PHASE2 | COMPLETED |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas |
PHASE2 | RECRUITING |
| BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors |
PHASE2 | WITHDRAWN |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer |
PHASE2 | RECRUITING |
| Palbociclib and Pembrolizumab In Central Nervous System Metastases |
PHASE2 | RECRUITING |
| Ribociclib and Letrozole Treatment in Ovarian Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. |
PHASE1/PHASE2 | COMPLETED |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer |
PHASE2 | COMPLETED |
| A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer |
PHASE1/PHASE2 | RECRUITING |
| Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 |
PHASE2 | RECRUITING |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors |
PHASE1/PHASE2 | COMPLETED |
| Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO |
PHASE2 | COMPLETED |
| A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers |
PHASE1 | COMPLETED |
| Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets |
PHASE1 | UNKNOWN |
| The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence |
nan | UNKNOWN |
| Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study |
nan | ACTIVE_NOT_RECRUITING |
| Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
nan | COMPLETED |
| Co'Moon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy |
nan | COMPLETED |
| Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a CCNI binder may also engage these)